Over the past four years, new donors have decreased by tens of thousands annually, indicating that the blood donor base is shrinking. Additionally, a national survey revealed some troubling disconnects between the public’s perception of blood donations and the realities of patient transfusion needs. Many are unaware of the frequency and need for blood. Given these significant challenges in engaging new donors for regular blood collection, recruitment of donors for specific types of special blood products faces additional hurdles to find suitable “golden” donors. This session will give insight to specific categories of challenging donors and why we need them. These include recruitment of donors for low titer Group O whole blood, granulocytes and antigen negative RBC components.
Underline how the attributes required for low titer whole blood restrict the eligible donor pool and create challenges for efficiently collecting sufficient volume to meet patient needs.
Describe the process used to identify granulocyte donors, their clinical evaluation to qualify them for WBC mobilization and the blood center resources required to both recruit and process recruited (directed) donors.
Describe the overall lack of diversity in the blood donor pool when compared to the US population and describe the impact on antigen negative RBC component availability and the additional efforts employed for recruitment of ethnically diverse donors.
Celgene: Advisory Committee I Global Blood Therapeutics: Advisory Committee - no honorarium I Pfizer: Advisory Committee - no honorarium I Novartis: Advisory Committee - no honorarium I Rockpointe: Advisory Committee - no honorarium
Pampee Young, MD, PhD :
Fresenius Kabi: Consultant | CTS: medical advisory board